Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1022-1026. doi: 10.19723/j.issn.1671-167X.2018.06.014

• Article • Previous Articles     Next Articles

Comparison of disease activities and extent measurements for anti-neutrophil cytoplasmic autoantibody-associated vasculitis

Sheng-guang LI1,(),Qing ZHANG2,Hui-qiong ZHOU2   

  1. 1. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
    2. Department of Rheumatology, Fouth Medical Center of PLA General Hospital, Beijing 100048, China
  • Received:2018-07-09 Online:2018-12-18 Published:2018-12-18
  • Contact: Sheng-guang LI E-mail:lishengguang@vip.sina.com

RICH HTML

  

Abstract:

Objective: To investigate the significance of a set of seven disease activities and extension measurements and their correlations between one and another for anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV).Methods:A total of 121 patients from Peking University International Hospital and Fouth Medical Center of PLA General Hospital with confirmed diagnoses of AAV clinically were enrolled in the study, including 15 cases of eosinophilic granulomatous with polyangiitis (EGPA), 59 cases of granulomatous with polyangiitis (GPA) and 47 cases of microscopic polyangiitis (MPA). A hundred and twenty-one AAV patients were divided into death group and survival group according to their survival conditions. A set of seven disease assessment scales including Birmingham vasculitis activity score (BVAS)-1994, BVAS-2003, as well as BVAS/GPA, vasculitis damage index (VDI), disease extent index (DEI), five factor score (FFS)-1996, and FFS-2009 were measured and scored one by one, and their relationships which were represented by Spearman correlation coefficient were compared between one and another.Results:BVAS-1994, BVAS-2003, as well as BVAS/GPA, VDI, DEI, and FFS, all of those seven evaluation indexes of the AAV patients in the death group were significantly higher than those in the survival group (P<0.05). Except for BVAS/GPA, all those above indicators in the patients with EGPA were lower than those in the patients with GPA and those in the patients with MPA, and those in all of the AAV patients as a whole group. There were high correlations among BVAS-2003, BVAS-1994 and BVAS/GPA (r values were 0.9 and 0.7, respectively); BVAS-1994 was fairly correlated with BVAS/GPA (r=0.69); FFS-1996 and FFS-2009 were highly correlated (r=0.73) with each other; BVAS-1994, BVAS-2003 and BVAS/GPA were fairly correlated with DEI (with r values of 0.62, 0.65, and 0.62, respectively); VDI was also fairly correlated with BVAS-1994 and with BVAS-2003 (r values were 0.49 and 0.52, respectively).Conclusion:All of those seven AAV assessment indicators above can be used as indicators of disease activity and prognosis in AAV patients, most of which were relevant within one and another. There were high correlations among BVAS-2003, BVAS-1994 and BVAS/GPA, and besides, there were also high correlations between FFS-1996 and FFS-2009.

Key words: Anti-neutrophil cytoplasmic antibody-associated vasculitis, Prognosis, Disease activities

CLC Number: 

  • R593.9

Table 1

Applications of AAV disease evaluation indexes in different types of AAV classifications (x-±s)"

Items EGPA (n=15) MPA (n=47) GPA (n=59) AAV (n=121)
BVAS-1994 16.2±8.4 23.5±6.0* 23.3±9.4* 22.5±8.4*
BVAS-2003 16.9±7.7 22.4±6.8* 22.8±9.8* 21.9±8.6*
VDI 3.1±2.5 4.2±2.5 4.0±2.4 4.0±2.5
DEI 8.2±3.1 7.8±2.8 8.9±3.2 8.4±3.0
FFS-1996 0.1±0.4 1.5±1.1* 0.9±1.0* 1.0±1.1*#
FFS-2009 0.1±0.4 1.4±0.9* 1.0±1.0*# 1.1±1.0*#

Table 2

Comparison of seven disease indicators in AAV patients"

Items Death group (n=25) Survival group (n=96) t P
Age/years 69±11 60±16 2.8 0.006
BVAS-1994 26.2±7.5 21.0±8.5 2.8 0.006
BVAS-2003 26.9±8.3 20.0±8.8 3.5 0.001
BVAS/GPA 8.3±4.9 5.9±2.9 2.2 0.031
VDI 5.8±2.4 3.5±2.2 4.6 <0.001
DEI 9.5±3.5 8.0±2.8 2.2 0.028
FFS-1996 1.5±1.2 0.9±1.0 2.7 0.008
FFS-2009 1.8±1.1 0.9±0.9 4.0 <0.001

Table 3

Spearman correlation coefficient of 7 AAV disease assessment scales"

Items BVAS-1994 BVAS-2003 BVAS/GPA VDI DEI FFS-1996 FFS-2009
BVAS-1994 1
BVAS-2003 0.90* 1
BVAS/GPA 0.69* 0.70* 1
VDI 0.49* 0.52* 0.37* 1
DEI 0.62* 0.65* 0.62* 0.37* 1
FFS-1996 0.44* 0.45* 0.23 0.31* 0.30* 1
FFS-2009 0.38* 0.39* 0.09 0.28* 0.23# 0.73* 1
[1] Jennette JC, Falk RJ, Bacon PA , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides[J]. Arthritis Rheum, 2013,65(1):1-11.
doi: 10.1002/art.37715 pmid: 23045170
[2] Yates M, Watts RA, Bajema IM , et al. EULAR/ERA-EDTA re-commendations for the management of ANCA-associated vasculitis[J]. Ann Rheum Dis, 2016,75(9):1583-1594.
[3] Lanham JG, Elkon KB, Pusey CD , et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome[J]. Medicine, 1984,63(2):65-81.
doi: 10.1097/00005792-198403000-00001
[4] Masi AT, Hunder GG, Lie JT , et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)[J]. Arthritis Rheum, 1990,33(8):1094-1100.
doi: 10.1002/art.1780330806 pmid: 2202307
[5] Leavitt RY, Fauci AS, Bloch DA , et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis[J]. Arthritis Rheum, 1990,33(8):1101-1107.
[6] Watts R, Lane S, Hanslik T , et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiolo-gical studies[J]. Ann Rheum Dis, 2007,66(2):222-227.
[7] Luqmani RA, Bacon PA, Moots RJ , et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis[J]. QJM, 1994,87(11):671.
[8] Eisenberger U, Fakhouri F, Vanhille P , et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome[J]. Nephrol Dial Transplant, 2005,20(7):1392-1399.
doi: 10.1093/ndt/gfh830
[9] Stone JH, Hoffman GS, Merkel PA , et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham vasculitis activity score[J]. Arthritis Rheum, 2001,44(4):912-920.
doi: 10.1002/(ISSN)1529-0131
[10] Exley AR, Bacon PA, Luqmani RA , et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides[J]. Arthritis Rheum, 2014,40(2):371-380.
doi: 10.1002/art.1780400222 pmid: 9041949
[11] De GK, Gross WL, Herlyn K , et al. Development and validation of a disease extent index for Wegener’s granulomatosis[J]. Clin Nephrol, 2001,55(1):31-38.
pmid: 11200865
[12] Guillevin L, Lhote F, Gayraud M , et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients[J]. Medicine, 1996,75(1):17-28.
doi: 10.1097/00005792-199601000-00003
[13] Guillevin L, Pagnoux C, Seror R , et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort[J]. 2011,90(1):19-27.
doi: 10.1097/MD.0b013e318205a4c6 pmid: 21200183
[14] Moiseev S, Novikov P, Jayne D , et al. End-stage renal disease in ANCA-associated vasculitis[J]. Nephrol Dial Transplant, 2017,32(2):248-253.
doi: 10.1093/ndt/gfw046 pmid: 27190338
[15] Greenan K, Vassallo D, Chinnadurai R , et al. Respiratory manifestations of ANCA-associated vasculitis[J]. Clin Respir J, 2018,12(1):57-61.
doi: 10.1111/crj.12478 pmid: 27059787
[16] Frausova D, Hruskova Z, Lanska V , et al. Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study[J]. Arthritis Res Ther, 2016(18):168.
doi: 10.1186/s13075-016-1055-5 pmid: 4944267
[17] 张清, 周惠琼, 郭娟 , 等. 抗中性粒细胞胞质抗体相关性血管炎死亡危险因素的探讨[J]. 中华医学杂志, 2017,97(43):3392-3395.
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[3] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[4] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[5] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[6] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[7] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[8] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[9] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[10] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[11] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[12] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
[13] Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269.
[14] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[15] Qian SU,Xin PENG,Chuan-xiang ZHOU,Guang-yan YU. Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 13-21.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!